A Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus Vulgaris
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Ianalumab (Primary)
- Indications Pemphigus vulgaris
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 16 Oct 2019 Status changed from active, no longer recruiting to completed.
- 01 Sep 2019 Planned End Date changed from 6 Aug 2019 to 23 Sep 2019.
- 01 Sep 2019 Planned primary completion date changed from 6 Aug 2019 to 20 Sep 2019.